| 前收盘价格 | 144.46 |
| 收盘价格 | 142.00 |
| 成交量 | 333,834 |
| 平均成交量 (3个月) | 164,944 |
| 市值 | 5,746,198,016 |
| 预期市盈率 (P/E Forward) | 227.27 |
| 股市价格/股市净资产 (P/B) | 7.29 |
| 52周波幅 | |
| 利润日期 | 10 Aug 2026 |
| 稀释每股收益 (EPS TTM) | -1.36 |
| 总债务/股东权益 (D/E MRQ) | 0.37% |
| 流动比率 (MRQ) | 25.98 |
| 营业现金流 (OCF TTM) | -29.23 M |
| 杠杆自由现金流 (LFCF TTM) | -13.42 M |
| 资产报酬率 (ROA TTM) | -22.23% |
| 股东权益报酬率 (ROE TTM) | -33.43% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Belite Bio, Inc | 看涨 | 看涨 |
AIStockmoo 评分
0.3
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.25 |
|
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 53.93% |
| 机构持股比例 | 0.75% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Darwin Global Management, Ltd. | 31 Mar 2026 | 3,057,412 |
| Eventide Asset Management, Llc | 31 Mar 2026 | 357,650 |
| Patient Square Capital Lp | 31 Mar 2026 | 116,684 |
| Duquesne Family Office Llc | 31 Mar 2026 | 106,100 |
| Mpm Bioimpact Llc | 31 Mar 2026 | 88,045 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合